BOD Australia (ASX:BDA)
- CEO:Jo Patterson
BOD Australia (ASX:BDA) Stock Price
Disclaimer: Past performance is not an indicator of future performance.
BOD Australia (ASX:BDA) Company Overview
Bod Australia (ASX: BDA) is a skin care and health product company that has been making waves thanks to its' patented "world-first" wafer system.
After launching a phase one clinical trial in July 2018, BOD managed to successfully dose its' proprietary phytocomplex cannabis extract—known as ECs315—in a sublingual wafer. This means that unlike other cannabis-based medicines, the ECs315 extract can be delivered via a wafer that is dissolved under the tongue.
Should the outcome of the clinical trial yield successful results, Bod will retain the rights to a unique, easily reproducible finished product with worldwide patent protection. The company is also broadening their use of the proprietary WaferiX technology and pursuing additional research initiatives which test the ECs315 extract on specific conditions such as post-chemotherapy nausea and vomiting.
Bod also produces a pharmaceutical-grade CBD oil called MediCabilis, and in November 2018 secured a deal with discount pharmacy giant, Chemist Warehouse, to distribute the medicine nationally. The company has a similar agreement with Priceline for its' MamaCare pregnancy supplement.
- Address:Level1, 377 New South Head Road, Double Bay, NSW 2028, Australia